Gastrodin as Adjuvant Therapy Improves Neuroprotective Effect in Acute Stroke Patients: A Systematic Review With Meta-analysis of Randomised Controlled Trials

IF 2.2 4区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Journal of Herbal Medicine Pub Date : 2024-05-21 DOI:10.1016/j.hermed.2024.100895
Xiaojiao Wu, Zelian Chen, Sishi Du, Liming Chang, Jian Zhang
{"title":"Gastrodin as Adjuvant Therapy Improves Neuroprotective Effect in Acute Stroke Patients: A Systematic Review With Meta-analysis of Randomised Controlled Trials","authors":"Xiaojiao Wu,&nbsp;Zelian Chen,&nbsp;Sishi Du,&nbsp;Liming Chang,&nbsp;Jian Zhang","doi":"10.1016/j.hermed.2024.100895","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Traditionally, gastrodin extracted from Rhizoma Gastrodiae has been used to treat various neurological diseases. The objective of this systematic review with meta-analysis is to evaluate the potential benefits of gastrodin as an adjuvant therapy for the treatment of acute stroke.</p></div><div><h3>Methods</h3><p>Relevant literature from multiple medical databases was searched until October 12, 2023, to identify randomised controlled trials investigating the use of gastrodin as an adjuvant therapy for acute stroke treatment. The total response rate and marked improvement rate were defined as &gt;18% and &gt;45% improvement in National Institutes of Health Stroke Scale score, respectively.</p></div><div><h3>Results</h3><p>A total of 12 randomised controlled trials, including 1 174 stroke patients, were identified. Compared to conventional treatment alone, the combination of gastrodin and conventional treatment significantly improved the total response rate (risk ratio 1.24; 95% CI 1.15–1.34) and marked improvement rate (risk ratio 1.37; 95% CI 1.18–1.59). Adjuvant treatment with gastrodin also resulted in a reduction in the National Institutes of Health Stroke Scale score (weighted mean difference [<strong>WMD</strong>] −3.08 points; 95% CI −3.75 to −2.41), haematoma volume (WMD −3.57 cm<sup>3</sup>; 95% CI −4.26 to −2.87), and blood neuron-specific enolase level (WMD −3.81 μg/l; 95% CI −6.21 to −1.41), as well as an increase in blood brain-derived neurotrophic factor level (WMD 0.81 ng/ml; 95% CI 0.50–1.12).</p></div><div><h3>Conclusions</h3><p>Gastrodin, when used as an adjuvant therapy, may yield additional beneficial effects in patients with acute stroke. However, future high-quality trials are necessary to further support this evidence.</p></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"46 ","pages":"Article 100895"},"PeriodicalIF":2.2000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Herbal Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210803324000526","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Traditionally, gastrodin extracted from Rhizoma Gastrodiae has been used to treat various neurological diseases. The objective of this systematic review with meta-analysis is to evaluate the potential benefits of gastrodin as an adjuvant therapy for the treatment of acute stroke.

Methods

Relevant literature from multiple medical databases was searched until October 12, 2023, to identify randomised controlled trials investigating the use of gastrodin as an adjuvant therapy for acute stroke treatment. The total response rate and marked improvement rate were defined as >18% and >45% improvement in National Institutes of Health Stroke Scale score, respectively.

Results

A total of 12 randomised controlled trials, including 1 174 stroke patients, were identified. Compared to conventional treatment alone, the combination of gastrodin and conventional treatment significantly improved the total response rate (risk ratio 1.24; 95% CI 1.15–1.34) and marked improvement rate (risk ratio 1.37; 95% CI 1.18–1.59). Adjuvant treatment with gastrodin also resulted in a reduction in the National Institutes of Health Stroke Scale score (weighted mean difference [WMD] −3.08 points; 95% CI −3.75 to −2.41), haematoma volume (WMD −3.57 cm3; 95% CI −4.26 to −2.87), and blood neuron-specific enolase level (WMD −3.81 μg/l; 95% CI −6.21 to −1.41), as well as an increase in blood brain-derived neurotrophic factor level (WMD 0.81 ng/ml; 95% CI 0.50–1.12).

Conclusions

Gastrodin, when used as an adjuvant therapy, may yield additional beneficial effects in patients with acute stroke. However, future high-quality trials are necessary to further support this evidence.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胃泌素作为辅助治疗可提高急性中风患者的神经保护效果:随机对照试验的系统回顾与荟萃分析
引言传统上,从天麻中提取的天麻素被用于治疗各种神经系统疾病。本系统综述和荟萃分析的目的是评估天麻素作为辅助疗法治疗急性脑卒中的潜在益处。方法检索多个医学数据库中的相关文献,直至 2023 年 10 月 12 日,以确定研究天麻素作为辅助疗法治疗急性脑卒中的随机对照试验。总反应率和明显改善率分别定义为美国国立卫生研究院卒中量表评分的>18%和>45%。与单用常规治疗相比,胃复安和常规治疗联合使用可显著提高总反应率(风险比 1.24;95% CI 1.15-1.34)和明显改善率(风险比 1.37;95% CI 1.18-1.59)。胃复安辅助治疗还可降低美国国立卫生研究院卒中量表评分(加权平均差 [WMD] -3.08分;95% CI -3.75至-2.41)、血肿体积(WMD -3.57立方厘米;95% CI -4.26至-2.87)和血液神经元特异性烯醇化酶水平(WMD -3.57立方厘米;95% CI -4.26至-2.87)。结论胃泌素作为一种辅助疗法,可为急性卒中患者带来额外的益处。结论胃泌素作为辅助疗法可为急性中风患者带来额外的益处,但还需要未来的高质量试验来进一步支持这一证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Herbal Medicine
Journal of Herbal Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
3.90
自引率
0.00%
发文量
94
期刊介绍: The Journal of Herbal Medicine, the official journal of the National Institute of Medical Herbalists, is a peer reviewed journal which aims to serve its readers as an authoritative resource on the profession and practice of herbal medicine. The content areas of the journal reflect the interests of Medical Herbalists and other health professionals interested in the clinical and professional application of botanical medicines. The objective is to strengthen the research and educational base of herbal medicine with research papers in the form of case studies, original research articles and reviews, monographs, clinical trials and relevant in vitro studies. It also publishes policy statements, opinion pieces, book reviews, conference proceedings and profession related information such as pharmacovigilance reports providing an information source for not only the Herbal Practitioner but any Health professional with an interest in phytotherapy.
期刊最新文献
Group B Strep During Pregnancy and Allium sativum L. The efficacy of flaxseed oil on non-alcoholic fatty liver disease: a randomised controlled trial Research progress and modern application analysis of chemical constituents and pharmacological effects of volatile oils in acrid Chinese medicines Clinical outcomes of hospitalised COVID-19 Omicron patients treated with traditional Chinese Medicine: A Retrospective Studymedicine: a retrospective study of a large medical centre in Shanghai, China Evaluating efficacy and safety of Saffron add-on treatment in improvement of motor and depressive symptoms of patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled clinical trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1